Doxapram as an Additive to Propofol Sedation in Sedation for ERCP

Doxapram as an Additive to Propofol Sedation in Sedation for ERCP - a Placebo controlled, randomized, double-blinded, prospective study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-003873-85-FI

Enrollment

Registered

2016-03-22

Start date

2016-04-12

Completion date

Unknown

Last updated

2021-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory depression caused by propofol sedation during an ERCP procedure

Interventions

Trade Name: Dopram Pharmaceutical Form: Solution for injection/infusion Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 25 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 25

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Contacts

Public ContactEndoscopy unit / HUCH

Helsinki University central Hospital

+3589 471 74688

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 28, 2026